News

In a recent webinar, Kristen Hsu of the Amyloidosis Research Consortium discussed the clinical trials currently being conducted for ATTR-CM.

People living with cardiac amyloidosis — both light chain cardiac amyloidosis (AL-CA) and transthyretin cardiac amyloidosis (ATTR-CM) — often experience high levels of anxiety and depression and would benefit from more support, according to a recent study published in the journal BMJ Open. To better understand the link between cardiac amyloidosis and mental health, researchers […]

People with the p.V142I variant, linked to hATTR-CM, are more likely to develop heart failure and atrial fibrillation starting in their 50s.

Major advancements have been made in recent years when it comes to treating ATTR-CM, which have positively affected patients’ lives.

Early recognition of ATTR-CM and the timely initiation of treatment can help secure better patient outcomes.

Patients with ATTR-CM who took both GLP-1RA and SGLT2i had lower death rates and fewer heart events than those on SGLT2i alone.

AI tools could help doctors to detect transthyretin amyloid cardiomyopathy (ATTR-CM) earlier and more fairly across different racial groups.

Cardiac transthyretin amyloidosis (ATTR-CM) was found in 12% of patients with Alzheimer’s disease and heart enlargement after death.

Tafamidis helps people with mixed-phenotype ATTR-CM live longer with fewer heart-related hospitalizations and deaths.

A new clinical trial evaluating the efficacy of nucresiran in treating transthyretin amyloid cardiomyopathy (ATTR-CM) is set to launch soon.